Replimune RP1 BLA Resubmission Accepted by FDA; PDUFA Date Set for April 10, 2026
Key Insights
The FDA accepted Replimune's BLA resubmission for RP1 plus nivolumab to treat advanced melanoma.
The PDUFA target action date is set for April 10, 2026.
The resubmission includes additional data and analyses addressing prior FDA feedback, considered a complete response to the July 2025&ref=yanuki.com complete response letter.
RP1 seeks approval for patients with advanced melanoma who have progressed on an anti-PD-1 containing regimen.
Why this matters: Acceptance of the BLA resubmission marks a significant step forward for Replimune, offering potential hope for patients with limited treatment options. The FDA's review process will determine if RP1 can provide a beneficial new therapy for advanced melanoma.
In-Depth Analysis
Replimune's RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy based on a herpes simplex virus strain. It is engineered with a fusogenic protein and GM-CSF to maximize tumor cell death, enhance immunogenicity, and activate a systemic anti-tumor immune response.
The resubmission addresses feedback from a complete response letter (CRL) issued by the FDA in July 2025&ref=yanuki.com. The FDA now considers the resubmission a complete response to the CRL, which allows the review process to move forward.
The therapy targets advanced melanoma patients who have progressed on anti-PD-1 therapies, representing a population with significant unmet medical needs.
Replimune is also exploring the potential of RP1 in combination with other treatment modalities, highlighting the versatility of the RPx platform.
FAQs
Q: What is the PDUFA date for RP1?
The FDA set a PDUFA target action date of April 10, 2026&ref=yanuki.com.
Q: What was the FDA's previous response to the RP1 application?
The FDA issued a complete response letter in July 2025&ref=yanuki.com, which Replimune has addressed in this resubmission.
Q: What patient population would benefit from RP1?
RP1 is intended for patients with advanced melanoma who have progressed on an anti-PD-1 containing regimen.
Key Takeaways
Replimune's RP1 has the potential to become a valuable treatment option for advanced melanoma patients who have progressed on anti-PD-1 therapy.
The FDA's acceptance of the BLA resubmission signifies a critical milestone in the drug's regulatory pathway.
Investors and patients should monitor the FDA's review process, with a decision expected by the PDUFA date of April 10, 2026&ref=yanuki.com.
Discussion
Do you think this trend will last? Let us know!
Share this article with others who need to stay ahead of this trend!
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer